Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Magnus Jaderberg"'
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, Thomas Birkballe Hansen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleura
Externí odkaz:
https://doaj.org/article/948af889fc44483eac5e19bcc3f77280
Autor:
Magnus Jaderberg, Victor Levitsky, Lukasz Kuryk, Sandeep Kumar, Alexander Shoushtari, Anne-Sophie Moller, Luis Paz Ares, Erik Digman Wiklund
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/df65f37ebb294a698d3b88b342e4f0d8
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7b6dc7621b064d579ed8757704182e8d
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f73b789c28e84aa895fb38bc8393d2d1
Publikováno v:
OncoImmunology, Vol 8, Iss 2 (2019)
Malignant melanoma is an aggressive type of skin cancer whose incidence is increasing globally. Although surgery is effective in early stage melanoma, patients with advanced melanoma only have a 20% 5-year survival rate. Hence, combinations of existi
Externí odkaz:
https://doaj.org/article/d1cd8bf9f2264b99bcbc7fd2d5e902dd
Autor:
Lukasz Kuryk, Anne-Sophie W Møller, Antti Vuolanto, Sari Pesonen, Mariangela Garofalo, Vincenzo Cerullo, Magnus Jaderberg
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 3, p 621 (2019)
Oncolytic adenoviruses can trigger lysis of tumor cells, induce an antitumor immune response, bypass classical chemotherapeutic resistance strategies of tumors, and provide opportunities for combination strategies. A major challenge is the developmen
Externí odkaz:
https://doaj.org/article/bb38ce9d13224380a00610a8ac456d38
Autor:
Luis Paz-Ares, Anne-Sophie W Møller, Charles Ricordel, Santiago Ponce Aix, Lukasz Kuryk, Sylvia Vetrhus, Susana Cedres, Victor Levitsky, Nicolas Isambert, Magnus Jaderberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMalignant pleural mesothelioma (MPM) is an aggressive malignancy without curative treatment. Standard of care (SOC) include pemetrexed/cisplatin and nivolumab/ipilimumab with median overall survival in unresectable disease of 12.1 months an
Autor:
Sandeep Kumar, Alexander N. Shoushtari, Victor Levitsky, Lukasz Kuryk, Erik Digman Wiklund, Anne-Sophie W Møller, Magnus Jaderberg, L. Arés
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundSolid tumors exhibit highly variable compositions of immune infiltrates. Therapeutic compounds driving uniform remodeling of tumor microenvironment (TME) across tumor types may improve the efficacy of cancer immunotherapy. ONCOS-102, a gran
Publikováno v:
Journal of Medical Virology
Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinica
Autor:
Erik Digman Wiklund, Lukasz Kuryk, Sandeep Kumar, Magnus Jaderberg, Victor levitsky, Thomas Birkballe Hansen, Anne-Sophie Moller, Alexander Shoushtari
Publikováno v:
Cancer Research. 82:1983-1983
Background: Defining molecular parameters of clinical response to immune modulators may lead to development of novel biomarkers, new therapeutic targets and drug combinations in cancer treatment. We recently completed phase I/II testing of ONCOS-102,